Kura Oncology Announces Updated Phase 1A Results From Ongoing FIT-001 Clinical Trial; Data Demonstrate Encouraging And Durable Clinical Activity Of Darlifarnib Plus Cabozantinib In Cabozantinib-Naïve Patients With Advanced Clear Cell Renal Cell Carcinoma
– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients –– Activity compares favorably with
Kura's cancer medicine test showed good results—half the patients improved, and they stayed better for over a year. When a medicine company shares strong test results like this, it hints the medicine might work well, which is worth watching as the company moves forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.